Advanced search×

Weekly Iron as a Safe Alternative to Daily Supplementation for Nonanemic Pregnant Women

Arch Med Res 37(5):9 (2006) PMID 16740440

Background: We undertook this study to compare the effectiveness and safety of antenatal daily and weekly supplementation with iron, folic acid, and vitamin B"1"2 in healthy, pregnant women who were not anemic at gestational week 20. Methods: Women with singleton pregnancies and blood hemoglobin (Hb) >115 g/L at gestational week 20 (equivalent to 105 g/L at sea level) were randomly assigned to two groups, one consuming one tablet containing 60 mg iron, 200 @mg folic acid and 1 @mg vitamin B"1"2 daily (DS, n = 56); the other consuming two tablets once weekly (WS, n = 60). Blood Hb and serum ferritin concentrations were measured every 4 weeks from weeks 20 to 36, and pregnancy outcomes were evaluated. Results: Mild anemia and hypoferritinemia throughout pregnancy occurred less frequently in DS than WS. None of the 116 women had Hb concentrations 145 g/L) from gestational week 28 onwards occurred in 11% in DS and 2% in WS. We observed ex post facto that hemoconcentration at gestational week 28 was associated with a significantly higher relative risk of low birth weight (RR 6.23, 95% CI 1.46-26.57) and premature delivery (RR 7.78, 95% CI 1.45-24.74). Conclusions: In women who were nonanemic at gestational week 20, both schemes (DS and WS) prevented the occurrence of Hb levels <100 g/L. DS women had a higher incidence of hemoconcentration. Hemoconcentration was associated with increased risk of low birth weight and premature delivery.

DOI: 10.1016/j.arcmed.2005.11.011
Version: za2963e q8zaf q8zb9 q8zce q8zd0 q8zec q8zf0 q8zg7

Similar articles you may find interesting…

  1. Gene therapy: concepts and methods. Few applications so far.
    Author(s) unavailable

    Prescrire Int 18(104):276-9 (2009) PMID 20027718

    (1) Gene therapy consists of inserting foreign genetic material into a patient's cells to correct a health disorder; (2) Only a fraction of gene therapy trials involve hereditary single-gene disorders. Most trials focus on acquired disorders such as cancer and cardiovascular disease; (3) The therape...